Skip to main content

Advertisement

SpringerLink
Log in

Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

The systemic immune-inflammation index (SII) is a new marker, defined as the platelet count × neutrophil-to-lymphocyte ratio. This study evaluates the SII as a prognostic marker for the overall survival (OS) of patients who underwent pancreatoduodenectomy (PD) for distal cholangiocarcinoma (DCC).

Methods

One hundred and forty patients who underwent PD for DCC between September, 2002 and December, 2015 at our hospital were divided into a low SII (SII < 1450) group and a high SII (SII ≥ 1450) group. We compared the clinicopathological characteristics and OS of the two groups retrospectively and used multivariate analyses to identify the prognostic factors for OS.

Results

The low and high SII groups comprised 119 and 21 patients, respectively. OS was better in the low SII group than in the high SII group, with median survival times of 81 and 26 months, respectively (p < 0.001). Multivariate analyses revealed that portal vein resection (hazard ratio [HR], 9.58; p < 0.001), SII ≥ 1450 (HR, 2.05; p = 0.041), microscopic venous invasion (HR, 2.04; p = 0.005), and pN1 (HR, 1.73; p = 0.034) were independently associated with poor survival.

Conclusion

The SII may be useful for predicting the long-term survival of patients with DCC after PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. van der Gaag NA, Kloek JJ, de Bakker JK, Musters B, Geskus RB, Busch OR, et al. Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Ann Oncol. 2012;23:2642–9 (official journal of the European society for medical oncology).

    Article  Google Scholar 

  2. Courtin-Tanguy L, Rayar M, Bergeat D, Merdrignac A, Harnoy Y, Boudjema K, et al. The true prognosis of resected distal cholangiocarcinoma. J Surg Oncol. 2016;113:575–80.

    Article  CAS  Google Scholar 

  3. Andrianello S, Paiella S, Allegrini V, Ramera M, Pulvirenti A, Malleo G, et al. Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long-term follow-up. Langenbecks Arch Surg. 2015;400:623–8.

    Article  Google Scholar 

  4. Byrling J, Andersson R, Sasor A, Lindell G, Ansari D, Nilsson J, et al. Outcome and evaluation of prognostic factors after pancreaticoduodenectomy for distal cholangiocarcinoma. Ann Gastroenterol. 2017;30:571–7.

    PubMed  PubMed Central  Google Scholar 

  5. Maeta T, Ebata T, Hayashi E, Kawahara T, Mizuno S, Matsumoto N, et al. Pancreatoduodenectomy with portal vein resection for distal cholangiocarcinoma. Br J Surg. 2017;104:1549–57.

    Article  CAS  Google Scholar 

  6. Zhou Y, Liu S, Wu L, Wan T. Survival after surgical resection of distal cholangiocarcinoma: a systematic review and meta-analysis of prognostic factors. Asian J Surg. 2017;40:129–38.

    Article  CAS  Google Scholar 

  7. Petrova E, Ruckert F, Zach S, Shen Y, Weitz J, Grutzmann R, et al. Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study. Langenbecks Arch Surg. 2017;402:831–40.

    Article  Google Scholar 

  8. Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, Ogata Y. Association of preoperative platelet-to-lymphocyte ratio with poor outcome in patients with distal cholangiocarcinoma. Oncology. 2019. https://doi.org/10.1159/000499050.

    Article  PubMed  Google Scholar 

  9. Kumamoto Y, Kaizu T, Tajima H, Nishizawa N, Ei S, Igarashi K, et al. Neutrophil-to-lymphocyte ratio as a predictor of postoperative morbidity in patients with distal cholangiocarcinoma. Mol Clin Oncol. 2018;9:362–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:75381–8.

    Article  Google Scholar 

  11. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107:695–9.

    Article  CAS  Google Scholar 

  12. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2014;23:1204–12 (a publication of the American association for cancer research, cosponsored by the American society of preventive oncology).

    Article  CAS  Google Scholar 

  13. Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23:6261–72.

    Article  Google Scholar 

  14. Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017;15:221.

    Article  Google Scholar 

  15. Huang L, Liu S, Lei Y, Wang K, Xu M, Chen Y, et al. Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection. Oncotarget. 2016;7:44185–93.

    Article  Google Scholar 

  16. Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, et al. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016;7:67142–9.

    Article  Google Scholar 

  17. Fujii T, Sugimoto H, Yamada S, Kanda M, Suenaga M, Takami H, et al. Modified blumgart anastomosis for pancreaticojejunostomy: technical improvement in matched historical control study. J Gastrointest Surg. 2014;18:1108–15.

    Article  Google Scholar 

  18. Sugiura T, Uesaka K, Okamura Y, Ito T, Yamamoto Y, Ashida R, et al. Adjuvant chemoradiotherapy for positive hepatic ductal margin on cholangiocarcinoma. Ann Gastroenterol Surg. 2020;4:455–63.

    Article  Google Scholar 

  19. Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192–202.

    Article  CAS  Google Scholar 

  20. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.

    Article  Google Scholar 

  21. Sobin LHWC, Gospodarowicz M, editors. TNM classification of malignant tumors (UICC). 7th ed. New York: Wiley-Blackwell; 2009.

    Google Scholar 

  22. Lin Y. Robust inference for responder analysis: innovative clinical trial design using a minimum p-value approach. Contemp Clin Trials Commun. 2016;3:65–9.

    Article  Google Scholar 

  23. Vanniyasingam T, Rodseth RN, Lurati Buse GA, Bolliger D, Burkhart CS, Cuthbertson BH, et al. Predicting the occurrence of major adverse cardiac events within 30 days of a vascular surgery: an empirical comparison of the minimum p value method and ROC curve approach using individual patient data meta-analysis. Springerplus. 2016;5:304.

    Article  Google Scholar 

  24. Peirce JC, Cornell RG. Integrating stratum-specific likelihood ratios with the analysis of ROC curves. Med Decis Mak. 1993;13:141–51.

    Article  CAS  Google Scholar 

  25. De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10:4895–900 (an official journal of the American association for cancer research).

    Article  Google Scholar 

  26. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010;16:219–23.

    Article  CAS  Google Scholar 

  27. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–90.

    Article  CAS  Google Scholar 

  28. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.

    Article  CAS  Google Scholar 

  29. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

    Article  CAS  Google Scholar 

  30. Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer. 2004;91:1711–7.

    Article  CAS  Google Scholar 

  31. Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. J Cell Mol Med. 2020;24:2993–3021.

    Article  Google Scholar 

  32. Murthy P, Zenati MS, Al Abbas AI, Rieser CJ, Bahary N, Lotze MT, et al. Prognostic value of the systemic immune-inflammation index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2020;27:898–906.

    Article  Google Scholar 

  33. De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, et al. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin Cancer Res. 2019;25:3839–46.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan

    Fumihiro Terasaki, Teiichi Sugiura, Yukiyasu Okamura, Takaaki Ito, Yusuke Yamamoto, Ryo Ashida, Katsuhisa Ohgi & Katsuhiko Uesaka

Authors
  1. Fumihiro Terasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teiichi Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yukiyasu Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takaaki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yusuke Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ryo Ashida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Katsuhisa Ohgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katsuhiko Uesaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teiichi Sugiura.

Ethics declarations

Conflict of interest

Fumihiro Terasaki and his co-authors have no conflict of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Terasaki, F., Sugiura, T., Okamura, Y. et al. Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma. Surg Today 51, 1602–1609 (2021). https://doi.org/10.1007/s00595-021-02312-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-021-02312-7

Keywords

Search

Navigation